Strategic partnerships Target potential CDMO and defense contractors with BIO 300 related to radiation countermeasures and oncology support, leveraging Lifecore Biomedical collaboration notes to position Humanetics as a versatile development partner for clinical and regulatory pathways.

Clinical collaboration Identify oncology and radiotherapy centers and contract research organizations that could pilot BIO 300 as a radiosensitizer or normal tissue protector, aligning with the ongoing partnerships and upcoming phase studies funded by DOD and NIAID.

Funding leverage Highlight opportunities tied to政府-funded initiatives and military health programs to potential investors and grant-focused stakeholders, emphasizing recent DOD investments and planned phase 2 studies for long-term lung injury protection.

Regulatory readiness Position for opportunities around regulatory consulting, manufacturing scale-up, and quality systems support to accelerate IND/clinical milestones, given the company’s clinical-stage profile and outsourcing engagements.

Executive access Leverage recent leadership hires and board additions to open doors with senior decision-makers in defense, government contracting, and specialty pharma, offering strategic alignments for co-development, licensing, or strategic investments.